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Abstract
Background: Complications of Ventolin as the most common drug used for bronchiolitis are wide-
ly known. The present study was conducted to determine the efficacy of hypertonic saline 3%, com-
pared with Ventolin, for treatment of acute bronchiolitis in children.
Methods: This double-blinded clinical trial study was conducted in Hajar Hospital, Shahrekord,
Iran, from 2011 to 2012. A total of 70 patients under the age of two years with bronchiolitis were
divided into two groups of 35 each. Ventolin nebulizer and hypertonic saline 3% nebulizer three
times per day were administered in the first (Ventolin) and second (Hypersaline) group, respectively.
The length of recovery was compared between the two groups. The data were analyzed by SPSS
software (version 22) using chi-square, t-test, paired t-test, and Mann-Whitney.
Results: The mean±SD length of recovery was 4.14±0.9 and 3.06±0.6 in the Ventolin and hyper-
saline groups, respectively. The mean duration of recovery was significantly lower in the hypersaline
group (p<0.001).
Conclusion: Hypertonic saline 3% nebulizer has more pleasant therapeutic effects on acute bron-
chiolitis than Ventolin. Therefore, use of hypertonic saline 3% nebulizer is recommended for the
treatment of acute bronchiolitis in children under two years old.
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Introduction
Acute bronchiolitis is the most frequent
reason for lower respiratory tract infection
and hospitalization due to respiratory dis-
ease in infancy. The frequent age of the
disease incidence is the first two years of
life. About 50000-80000 hospitalizations of
the infants under the age of one are at-
tributed to this disease in the USA (1). The
severe form of this disease is much more
prevalent in one- to three-month-old infants
and responsible for more than 50% of its
incidence, causing respiratory syncytial vi-
rus, inflammation and small airway ob-
struction (1). Clinical symptoms of acute
bronchiolitis are similar to those of viral
pneumonias, with fever, wheezing, and in-
creased respiratory rate as the most im-
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portant ones (2).
Research is needed to find the appropriate
treatment for this disease. The treatment is
often supportive therapy, including fluid
therapy, anti-fever drugs, and oxygen (3).
Some investigations have been recently
conducted on the therapies like bronchodi-
lators including salbutamol and epinephrine
as nebulized (2,4). In infants particularly
under age of six months, edema and in-
flammation in bronchioles could lead to
respiratory distress because of small diame-
ter of airways (1).
There is no consensus on use of broncho-
dilators and/or beta-agonists (5,6). Most
works have indicated that bronchodilators
have no role in treating these patients (7).
Today, inhaled salbutamol (Ventolin) is
used for treating bronchiolitis patients in
Iran’s hospitals while several studies have
indicated that this drug does not work (8-
12). In many studies, the positive effect of
hypertonic saline has been observed on re-
covering bronchiolitis symptoms (9,10).
Also, some studies comparing different
concentrations of hypertonic saline have
obtained similar results. For example, com-
parative study of hypertonic saline 3% and
7% indicated a greater therapeutic effect of
hypertonic saline 3% than that of hyperton-
ic saline 7% in treating bronchiolitis symp-
toms and decreasing duration of treatment
(13,14). Hypertonic saline 3% was also
found as better and more efficient than
normal saline and hypersaline 3% nebulizer
(15,16).
In addition, a research conducted to com-
pare hypertonic saline 3% with the drugs
used for bronchiolitis like Ventolin indicat-
ed that hypertonic saline 3% and Ventolin
had a greater therapeutic effect than Ven-
tolin and normal saline on treating bronchi-
olitis symptoms (17). In some studies, Ven-
tolin and hypertonic saline 3% had similar
therapeutic effect on symptoms developed
by mild to moderate viral bronchiolitis and
were free of complications, as well (18).
Regarding the widely known complications
of Ventolin as the most common drug used
for bronchiolitis and that no study has been
yet conducted to compare the efficacy of
Ventolin and hypertonic saline 3% on
bronchiolitis in Iran, the present study was
conducted to determine the efficacy of hy-
pertonic saline 3% on treatment of acute
bronchiolitis, in comparison with Ventolin.
Methods
This research is a double-blinded clinical
trial study conducted in 2011-2012 on 70
referring patients with acute viral bronchio-
litis. Registration code of IRCT
2012110510222N2 was issued by Iranian
Registry of Clinical Trials for this study.
The samples of study were examined for
severity of simulated disease prior to en-
rollment and the patients with acute status
and causing a predetermined error in the
study were excluded from the investigation.
Inclusion criteria were patients with mild to
moderate respiratory status, the first wheez-
ing, and obtaining a score of lower than
nine in Respiratory Distress Assessment
Inventory (RDAI), the most common clini-
cal scoring tool for acute bronchiolitis de-
veloped based on wheezing and intercostal
retraction (19). All patients were frequently
visited and examined by a pediatrician in
Hajar Hospital, Shahrekord, Iran till com-
pletion of their hospitalization. After the
informed consent was obtained from the
patients’ guardians, the patients were as-
signed into two groups of case and control.
Group one underwent treatment with Ven-
tolin nebulizer and group two with hyper-
tonic saline 3% nebulizer. The prescribed
dose of Ventolin was 0.1 mg/kg and the
required concentration was obtained by dis-
tilled water. To obtain hypertonic saline 3%
solution, 3 ml sodium chloride 5% was
mixed with a 5-cc vial of distilled water.
The two medicinal combinations were ad-
ministered to the patients of the two groups
every four hours by a nebulizer instrument.
The inhaled medicine accompanied with
oxygen was nebulized to the patients by a
face mask. Other therapies including oxy-
gen and fluid therapy were used for all pa-
tients. Clinical symptoms of the patients
and the length of recovery since hospitali-
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zation initiation were calculated for each
patient and registered in a special checklist
based on the defined RDAI criterion and
day. The data were analyzed by SPSS soft-
ware (version 22) using chi-square, t-test,
paired t-test, and Mann-Whitney.
Results
In this study, 70 patients were randomly
assigned to two groups of 35 each. Group
one underwent treatment with Ventolin
nebulizer (Ventolin group) and group two
with hypertonic saline 3% nebulizer
(Hypersaline group). The mean±SD age of
the patients was 14.1±5.6 months in the
Ventolin group and 12.6±5.6 months in the
hypersaline group.
The mean±SD length of recovery was
4.14±0.9 days in the Ventolin group and
3.06±0.6 in the hypersaline group. The
mean length of recovery was significantly
lower in the hypersaline group (p<0.001).
The mean±SD RDAI criterion on the days
two, three, four, and five was respectively
5.68±1.3, 4.85±1.6, 3.62±1.6, and 1.42±0.8
in the Ventolin group and 4.25±1.5,
3.2±1.5, 2.54±1.6, and 0.9±0.54 in the
hypersaline group; the mean RDAI criteri-
on was significantly lower in the hyper-
saline 3% group (p<0.001).
Discussion
The general purpose of conducting this
study was to compare the efficacy of hyper-
tonic saline 3% with that of Ventolin on
treating acute bronchiolitis in the children
under two years. In this study, two groups
(35 patients in each group) of infants hospi-
talized for bronchiolitis in Hajar Hospital,
Shahrekord, Iran were investigated. Ac-
cording to the results of this study, the
mean length of recovery was 4.14±0.4 days
in the Ventolin group and 3.0±0.6 in the
hypersaline group. The patients under
hypersaline treatment recovered more rap-
idly, which is clinically and economically
important as 50000-80000 hospitalizations
of under one-year-old infants has led to ex-
pending about 300 million dollars per year
in the USA (1). Other studies reported the
therapeutic effect of hypertonic saline 3%
on acute bronchiolitis in children.
In Kuzik et al study, use of hypertonic sa-
line 3% nebulizer had more pleasant out-
comes than the normal saline nebulizer
(15). Also, Anil et al who used some me-
dicinal combinations (Ventolin nebulizer
with normal saline, epinephrine with nor-
mal saline and hypertonic saline 3%, and
normal saline alone) for treating acute
bronchiolitis in the children found no sig-
nificant difference among the groups; the
effect of hypertonic saline 3% was similar
to that of other medicinal combinations (9).
In Zhang et al study, hypertonic saline 3%
was more effective than normal saline (16).
Mandelberg et al compared hypertonic sa-
line 3% nebulizer, epinephrine, and normal
saline and found hypertonic saline 3% as
therapeutically more effective on bronchio-
litis symptoms (13). In Ater et al study to
compare Ventolin nebulizer and normal
saline with Ventolin and hypertonic saline
5%, hypertonic saline 5% had a better ther-
apeutic effect in the children with bronchio-
litis than normal saline (20).
In addition, the decreased length of hospi-
talization after hypertonic saline 3% was
observed in some studies (10,13,17,20).
The results of this study indicated that the
mean RDAI criterion on the day of hospi-
talization and prior to treatment initiation
had no significant difference between the
two groups. The RDAI criterion indicating
the disease severity had no significant dif-
ference between the two groups of study. In
addition, the mean RDAI criterion was sig-
nificantly lower in the hypertonic saline 3%
group, indicating that use of hypertonic sa-
line 3% nebulizer was obviously more effi-
cient than Ventolin after hospitalization
(the day one), i.e. from the day two to the
last day of hospitalization. The greatest ef-
ficacy was noted on the day two after hy-
pertonic saline 3%, irrespective of the last
day of hospitalization. In Sarrell et al study,
there was no significant difference prior to
study between the two groups, but an obvi-
ously better effect was noted by the use of
hypertonic saline 3% nebulizer between the
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day two and the last day of hospitalization.
However, the highest effect was observed
in the day two. The effect of hypertonic
saline 3% was obviously better than that of
normal saline on the day one in Sadbhavna
et al study, but no difference was observed
between the two groups on the day two
(17,21).
The length of hospitalization in our study
was 2-6 days, similar to other studies
(13,15,16). Although the mechanism of hy-
pertonic saline 3% was not examined in the
present work, hypertonic saline 3% was
demonstrated to increase mucus clearing in
Dasgupta et al study (22). Also, Tomooka
et al examined the effects of hypertonic sa-
line on recovery of respiratory symptoms.
These effects included improvement of
mucous cilia’s function, decrease in mu-
cous edema and inflammatory mediators,
mechanical clearing of secretions, and im-
provement of mucus function (23). On the
other hand, no complication was observed
by the use of hypertonic saline 3% nebuliz-
er throughout the study in the studied pa-
tients, which is consistent with other stud-
ies (9,13,18).
Conclusion
Regarding the obtained results in this
study and comparing them with those of
other studies, we found hypertonic saline
3% nebulizer as having more pleasant ther-
apeutic effects than Ventolin on treating
acute bronchiolitis in the children under
two years. Moreover, use of hypertonic sa-
line 3% leads to no remarkable drug-related
complications in the children; the reason is
that it is free of medicinal compounds. In
addition, the treatment costs would decline
considerably and hence use of hypertonic
saline 3% nebulizer is recommended for
treatment of acute bronchiolitis in children
under the age of two.
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